Switching from ustekinumab originator to biosimilar: No adverse impact on inflammatory bowel disease control and well tolerated by patients in a UK multicentre study. - Sharma, E.; Allah-Ditta, M.; Povlsen, S.; Greenwood, J.; Shinh, S.; Omrani, F.; Raftis, K.; Leason, G.; Rousseau, C.; Cattermull, M.; Leung, N.; Sonwalkar, S.; et al. (Journal of Crohn's & Colitis, 2026)